em Clin Exp Rheumatol /em 2001;19:S1C9. of congestive heart failure-related AEs, demyelinating disease, lupus-like syndrome, malignancies, tuberculosis or deaths were reported. JIA ACR OPD2 30/50/70/90 reactions Trapidil and JADAS27 LDA were accomplished in 66% to 96% of individuals at week 104, and 63 (37%) individuals Trapidil achieved medical remission (JADAS27 ID sustained for 6 continuous Trapidil months) during the study. Attainment of JIA ACR 50 or higher and JADAS27 LDA or ID in the initial weeks were the best predictors of medical remission. Mean JADAS27 decreased from baseline, 22.5 (n=170), to 2.5 (n=30) at week 312 (observed analysis). Conclusions Through 6?years of exposure, adalimumab was well tolerated with significant clinical response (up to clinical remission) and a relatively low retention rate. 2018;70, product 10). Footnotes Contributors: The study was designed jointly by academic authors (DJL, HIB, AM and NR) and AbbVie, with data collected by PRINTO/PRCSG investigators. All authors experienced full access to study data, examined and revised the manuscript, and approved the final version to be published. All authors were involved in the decision to post the manuscript for publication and experienced the right to accept or reject feedback or suggestions. Funding: This study was funded by AbbVie. Competing interests: DJL offers served on loudspeakers bureaus for Genentech and Bristol-Myers Squibb and on data and security monitoring boards for Forest Study and the National Institutes of Health-NIAMS. Cincinnati Childrens Hospital Medical Center offers received consulting charges from AbbVie, AstraZeneca, Centocor, Bristol-Myers Squibb, Pfizer, Regeneron, Hoffman La-Roche, Novartis, UBC, Xoma and Genentech for the work of DJL. HIB offers received speaker honoraria and consulting charges from AbbVie, AstraZeneca, Centocor, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Regeneron, Hoffman La-Roche, Novartis, Takeda, UCB, Genentech, Lilly, Janssen, EMD Serono and R-Pharm; and offers served on loudspeakers bureaus for Genentech and Novartis. AOR offers received consulting charges and speaker charges from AbbVie and Novartis. LJ offers served like a specialist for OncoImmune and Novartis; offers received unrestricted education grants from AbbVie; offers received medical trial support from AbbVie, Bristol-Myers Squibb and UCB Biosciences; and offers served on a data and security monitoring table for Bristol-Myers Squibb. KJ offers nothing to disclose. DN has nothing to disclose. RM offers received honoraria from AbbVie like a co-investigator during this medical trial. CS offers nothing to disclose. JFB has nothing to disclose. DE offers received research Trapidil grants, consulting charges and/or speakers charges from AbbVie. CG offers nothing to disclose. GH has nothing to declare. IK-P offers received consulting charges from AbbVie, Pfizer, Roche, CHUGAI, Novartis, SOBI and Novimmune. OYJ has nothing to disclose. VV offers received speaker charges from AbbVie and Pfizer. EC offers received speaker charges from AbbVie. CW offers received research grants to her institution from Roche, Pfizer and GSK. IL and YS are full-time employees of AbbVie and may hold stock or stock options. AM is definitely a professor of pediatrics in the University or college of Genoa, Italy, and offers consultancy agreements with Janssen, Novartis and Pfizer. Prior to January 2019, AM was a medical director of the Giannina Gaslini Hospital and performed consultancy activities on behalf of the Gaslini Institute for the following companies: AbbVie, Biogen, Boehringer, Bristol-Myers Squibb, EMD Serono, Janssen, Novartis, Pfizer, and R-Pharm. NR is definitely a full-time employee of the Gaslini Hospital, which has received contributions to support the research activities of.